ニュース、リソース、最新情報
当社の最新の研究動向や企業情報をお届けする科学情報拠点です。
最新の心血管・代謝研究ニュース
InnoSerは、げっ歯類におけるゴールドスタンダードとなる心代謝疾患モデルを提供し、貴社の創薬候補の非臨床開発を最適化するためのカスタム研究を支援します。InnoSerの心血管分野における経験と専門知識をどのように活用できるか、詳細をご覧ください。
ADPKDマウスモデルにおけるPK/PDおよび忍容性試験
The lead optimisation phase is a crucial process during which you investigate and select the most promising preclinical candidate(s) to progress to efficacy testing using animal models of human diseases. Pharmacokinetic (PK) and Pharmacodynamic (PD) profiling helps...
治療薬の安全性を評価するための生体内腫瘍形成性試験
For all novel therapy types in the immuno-oncology field such as immunotherapies, small molecule, biologics, ATMPs, gene therapeutics etc., rigorous preclinical research is the key to success in clinical trials. Learn more about how InnoSer’s expertise in the oncology...
神経変性疾患の研究モデルから最大限の価値を引き出すには？
To date, large ongoing efforts are being made to provide well-characterised animal models which are suitable for investigating novel therapeutics. To ensure full confidence in the efficacy profile of novel therapeutic agents, efficacy testing often needs to be...
InnoSer、AD/PD 2024で、in vitroにおける神経変性疾患のモデル化能力を示す新たなデータを発表へ
We are thrilled to announce that InnoSer, as an innovative preclinical contract research organization (CRO), will be actively participating in the upcoming AD/PD 2024 Conference taking place in Lisbon, Portugal on March 5-9, 2024. The theme of AD/PD 2024 is striving...
研究において生物発光イメージングを最大限に活用する
The application of bioluminescence imaging (BLI) in preclinical research studies offers quantitative, sensitive, longitudinal real-time data and can be applied in: Validation of cancer cell lines, helping to establish improved preclinical cancer mouse models. ...
info@innoserlaboratories.com